Trial Profile
Risk of Guillain-Barré syndrome following meningococcal conjugate (MCV4) vaccination
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal infections
- Focus Adverse reactions
- 15 Mar 2017 Status changed from active, no longer recruiting to completed.
- 14 Jan 2008 New trial record.